Industry
Company news, device launches, earnings, and market intelligence
Filter by Company
Self-expanding TAVR valves from Medtronic, Abbott consistently linked to positive outcomes
Self-expanding TAVR valves from Medtronic and Abbott demonstrate consistent positive clinical outcomes in comparative analyses. The findings support the sustained performance profile of these platforms in transcatheter aortic valve replacement procedures.
Digest: These data reinforce operator confidence in self-expanding valve technology and may influence device selection strategies among interventional cardiologists, particularly in anatomies where self-expanding platforms offer theoretical advantages.
Abbott kicks off new research on software-guided, balloon-expandable TAVR system
Abbott has initiated new research on a software-guided, balloon-expandable transcatheter aortic valve replacement system. No specific clinical data or trial endpoints were provided in the article content.
Digest: Abbott's entry into balloon-expandable TAVR with software guidance could challenge Edwards and Medtronic's market dominance and potentially improve procedural precision and outcomes.
TAVR with a Trilogy valve shows promise for LVAD patients with AR
TAVR using the Trilogy valve demonstrated feasibility for treating aortic regurgitation in patients with left ventricular assist devices. The study represents a novel application of transcatheter techniques in a complex patient population with limited treatment options.
Digest: Addresses an unmet clinical need for LVAD patients who develop AR, a complication that complicates device management and has traditionally required high-risk open surgery.

Device shows benefit in severe tricuspid regurgitation
The CLASP II TR trial randomized 450 patients with symptomatic severe tricuspid regurgitation to transcatheter tricuspid valve repair with the Pascal Precision system (Edwards Lifesciences) versus optimal medical therapy alone. At 1 year, the device improved health status and reduced TR severity compared with medical therapy, though no significant difference was observed in mortality or heart failure hospitalization.
Digest: This represents the first randomized controlled trial data for the FDA-approved Pascal Precision system in tricuspid regurgitation, providing evidence for transcatheter intervention in a valve position historically undertreated and associated with poor outcomes.
Cardiologist explains why TAVR may be beneficial for select patients with moderate aortic stenosis
A cardiologist discusses the potential role of TAVR in treating select patients with moderate aortic stenosis, an indication that extends beyond current approved severe AS populations. The article explores clinical rationale for expanding TAVR use to patients with less advanced valvular disease.
Digest: Expansion of TAVR to moderate AS represents a significant potential market growth opportunity and would fundamentally shift treatment paradigms for earlier-stage aortic valve disease.
NCD and the dawn of a new era: What expanded TAVR coverage means for patient care
The CMS National Coverage Determination (NCD) has expanded Medicare coverage for transcatheter aortic valve replacement, broadening patient eligibility criteria beyond previous restrictions. This policy change enables reimbursement for TAVR in a wider population of patients with aortic stenosis, including potentially lower-risk cohorts previously subject to coverage limitations.
Digest: Expanded NCD coverage removes reimbursement barriers that may have limited TAVR adoption despite FDA approval across risk strata, potentially accelerating market penetration and influencing treatment decisions for structural heart teams.
Medtronic studying safety, effectiveness of its self-expanding TAVR valves in patients with moderate AS
Medtronic has initiated a clinical study evaluating the safety and effectiveness of its self-expanding transcatheter aortic valve replacement (TAVR) systems in patients with moderate aortic stenosis. The trial represents an expansion into earlier-stage disease beyond current severe symptomatic AS indications.
Digest: This trial could potentially expand TAVR treatment paradigm to moderate AS patients, representing a significant market opportunity and earlier intervention strategy that would shift current guidelines recommending watchful waiting.
Abbott Begins Enrollment in Global Trial of Investigational Mitral Valve Replacement System
Abbott has initiated enrollment in a global clinical trial evaluating its investigational transcatheter mitral valve replacement system. No specific enrollment targets, trial design details, or timeline information were provided in the article.
Digest: This represents Abbott's strategic entry into the competitive TMVR market, currently dominated by early-stage investigational devices from Edwards and Medtronic.
GE HealthCare Introduces Ceiling-Mounted Image Guiding System
GE HealthCare has launched a ceiling-mounted image guiding system for interventional procedures. No specific clinical performance data or technical specifications were provided in the brief announcement.
Digest: Advanced imaging systems are critical infrastructure for structural heart interventions including TAVR and TMVR, potentially improving procedural visualization and workflow efficiency.
Medtronic Presents Design and Baseline Characteristics of Patients in the Evolut EXPAND TAVR II Trial
Medtronic presented the trial design and baseline patient characteristics from the Evolut EXPAND TAVR II trial. The presentation provides foundational data on the patient population enrolled in this ongoing clinical investigation of the Evolut transcatheter aortic valve platform.
Digest: Understanding baseline characteristics and trial design is essential for interpreting future outcomes data and assessing the applicability of results to real-world TAVR populations.
GE HealthCare Adds AI-assisted Capabilities for Vscan Air Handheld Ultrasound System
GE HealthCare has added AI-assisted capabilities to its Vscan Air handheld ultrasound system. No specific clinical data or performance metrics were provided in the announcement.
Digest: Enhanced point-of-care ultrasound capabilities may improve bedside structural heart assessment and procedural guidance, though clinical validation data are needed.

TAVR benefits high-risk patients with moderate aortic stenosis
The PROGRESS trial demonstrated that TAVR with a balloon-expandable valve reduced the risk of death or heart failure events at 2 years compared with clinical surveillance in high-risk patients with moderate aortic stenosis and at-risk features. The primary safety outcome at 30 days occurred in 5.9% of patients, meeting the performance goal, while the primary effectiveness outcome at 2 years occurred in 16.7% of the TAVR group.
Digest: This randomized trial challenges current practice by demonstrating clinical benefit of early intervention in moderate aortic stenosis, potentially expanding TAVR indications beyond severe disease in selected high-risk patients.
Abbott Announces 30-day Clinical Trial Results for Coronary Intravascular Lithotripsy System
Abbott announced 30-day results from a clinical trial evaluating its coronary intravascular lithotripsy (IVL) system for treating calcified coronary artery lesions. The trial assessed safety and performance of the device in modifying severely calcified coronary lesions prior to stenting.
Digest: This represents Abbott's entry into the coronary IVL space, a market currently dominated by Shockwave Medical, and could expand treatment options for complex calcified coronary disease that structural heart teams encounter in TAVR and other transcatheter procedures.

Deaths from heart valve disease rising among U.S. adults ages 65 and older
Valvular heart disease mortality among U.S. adults aged 65 and older increased nearly 5% from 2018 to 2023, reversing a two-decade decline. Death rates rose from 104 to 109 per 100,000, with highest impact among men, non-Hispanic white adults, adults 85 and older, and nonmetropolitan residents.
Digest: Rising VHD mortality despite advances in transcatheter therapies signals potential gaps in early detection and access to valve interventions in aging and rural populations, informing market opportunity and healthcare delivery strategies.
EARLY TAVR update: New data highlight economic benefits of treating asymptomatic aortic stenosis
New health economic data from the EARLY TAVR trial demonstrate cost-effectiveness of transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis. The analysis supports earlier intervention before symptom onset in appropriately selected patients.
Digest: Cost-effectiveness data may influence payer coverage decisions and clinical adoption of TAVR in asymptomatic patients, a potentially large untreated population that could significantly expand the structural heart market.
Abbott now enrolling patients for new research on Cephea mitral valve replacement device
Abbott has initiated patient enrollment for a new clinical study evaluating the Cephea transcatheter mitral valve replacement system. The trial represents continued development of Abbott's TMVR platform for treating mitral valve disease.
Digest: This enrollment milestone advances Abbott's competitive position in the developing TMVR market, where multiple platforms are vying for clinical validation and eventual regulatory approval.
Long-term data support durability and sustained outcomes with balloon-expandable TAVR valves
Long-term follow-up data demonstrate sustained performance and structural durability of balloon-expandable transcatheter aortic valve replacement systems. The findings support extended valve longevity beyond initial trial periods.
Digest: Long-term durability data are critical for expanding TAVR into younger, lower-risk patient populations and supporting lifetime management strategies in structural heart disease.

PVL Occluder Receives FDA Clearance
Abbott received FDA approval for the Amplatzer Paraclose PVL Occluder, the first transcatheter device specifically designed to treat paravalvular leak following surgical valve replacement. The approval was supported by the PARADIGM study, a prospective multicenter trial of 200 patients demonstrating effective minimally invasive closure of PVL as an alternative to repeat open-heart surgery.
Digest: This approval addresses a significant unmet need for the 5-17% of surgical valve replacement patients who develop paravalvular leak, providing the first purpose-built transcatheter solution to avoid repeat cardiac surgery.
Is surgical backup still necessary during TAVR? Opinions are mixed as bailout risk decreases
Debate continues regarding the necessity of on-site surgical backup during transcatheter aortic valve replacement procedures as complication rates requiring emergency conversion have decreased. The discussion reflects evolving procedural safety profiles and institutional experience with TAVR across different risk categories.
Digest: Resolution of the surgical backup requirement could expand TAVR availability to non-surgical centers and reduce procedural costs, though implications for patient safety and regulatory standards remain contentious.

FDA Approves Transcatheter Tricuspid Valve Repair System
The FDA approved Edwards Lifesciences' PASCAL Precision system for transcatheter edge-to-edge repair (T-TEER) in patients with symptomatic severe tricuspid regurgitation at intermediate or greater surgical risk. Additionally, the FDA approved the PASCAL Ace with Capture Clarity system for degenerative mitral TEER, featuring the first fluoroscopic indicators to confirm leaflet capture.
Digest: Edwards becomes the only company offering both transcatheter repair and replacement therapies for mitral and tricuspid valves in the U.S., expanding treatment options for TR patients and introducing novel fluoroscopic confirmation technology to simplify TEER procedures.

FDA approves new tricuspid valve repair system
The FDA approved Edwards Lifesciences' PASCAL Precision system for transcatheter tricuspid valve repair in patients with symptomatic severe tricuspid regurgitation at elevated surgical risk despite optimal medical therapy. Approval was based on 1-year results from the CLASP TR trial of 65 patients demonstrating significant improvement in tricuspid regurgitation severity with durable outcomes.
Digest: This approval expands the transcatheter treatment options for severe tricuspid regurgitation in the US market, addressing a historically underserved patient population with limited therapeutic alternatives.
FDA approves Pascal Precision system from Edwards Lifesciences for tricuspid valve repair
The FDA has approved Edwards Lifesciences' Pascal Precision system for transcatheter tricuspid valve repair. This represents regulatory clearance for Edwards' edge-to-edge repair platform to treat tricuspid regurgitation.
Digest: This approval provides interventional cardiologists with another transcatheter option for treating tricuspid regurgitation, expanding the competitive landscape in the emerging TTVR market.
FDA shares warning about Edwards Lifesciences heart valve tech after patient death
The FDA issued a safety warning regarding Edwards Lifesciences heart valve technology following a patient death. The agency is alerting healthcare providers and patients about potential safety concerns associated with the device.
Digest: FDA safety communications regarding transcatheter heart valve platforms can impact clinical decision-making, device utilization patterns, and inform risk-benefit discussions with patients undergoing valve interventions.
Cardiology’s busy year: Compensation, productivity, imaging volumes and TAVR cases all on the rise for heart specialists
Cardiology practices reported increased compensation, productivity, imaging volumes, and TAVR case volumes in the most recent reporting period. The data reflects growing demand for cardiovascular services with specific expansion in transcatheter aortic valve replacement procedures.
Digest: Rising TAVR volumes and cardiologist productivity metrics indicate sustained market growth and increasing procedural adoption, relevant for capacity planning and market forecasting in structural heart.
Physicians support Medicare coverage for TAVR in patients with aortic regurgitation
Physicians are advocating for Medicare coverage expansion to include transcatheter aortic valve replacement for patients with native aortic regurgitation. This represents a push to extend TAVR reimbursement beyond the currently covered indication of aortic stenosis.
Digest: CMS coverage for TAVR in aortic regurgitation would open a new market segment and provide reimbursement for an off-label use that some operators are already performing with dedicated or adapted devices.
Canon launches new TAVR technology to help structural heart programs meet rising demand
Canon has launched new TAVR technology designed to help structural heart programs address increasing procedural demand. No specific clinical data or device specifications were provided in the announcement.
Digest: New imaging or support technology from Canon could enhance procedural efficiency and capacity as TAVR volumes continue to expand across risk categories.
CMS considers covering TAVR for aortic regurgitation
CMS is considering coverage for transcatheter aortic valve replacement (TAVR) in patients with aortic regurgitation. This would represent a significant expansion beyond the current approved indication of aortic stenosis.
Digest: CMS coverage for TAVR in aortic regurgitation would open a new market segment and provide reimbursement for an off-label use that has shown feasibility in selected patients but lacks robust trial data.

FDA Approves Surgical Pulmonary Valve for Pediatric Patients
The FDA approved Edwards Lifesciences' AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed for pediatric congenital heart disease patients that can be expanded transcatheter as the child grows. The pivotal study met primary endpoints with 100% freedom from device-related complications at 30 days, no reinterventions at 6 months, and at 1 year all patients maintained RVOT mean gradients ≤40 mmHg with less than moderate pulmonary regurgitation.
Digest: This approval addresses a significant unmet need in pediatric congenital heart disease by potentially reducing the number of repeat open-heart surgeries through transcatheter valve expansion, representing a paradigm shift in long-term care planning for this vulnerable population.

FDA approves pediatric pulmonary valve that grows with patients
The FDA approved the Autus Size-Adjustable Valve from Edwards Lifesciences, the first pulmonary valve replacement designed to expand with patient growth, reducing repeat surgeries in pediatric congenital heart disease. The pivotal study of 62 patients aged 18 months to 16 years demonstrated 100% freedom from device-related complications at 30 days, no reinterventions at 6 months, and favorable hemodynamics through 1 year with mean RVOT gradients ≤40 mmHg and less than moderate regurgitation.
Digest: This first-in-class balloon-expandable valve (13-22 mm) with polymeric leaflets addresses a critical unmet need in pediatric congenital valve disease by potentially eliminating multiple open-heart surgeries during childhood growth.
FDA clears AI tool for detecting undiagnosed heart valve disease in ECGs
The FDA cleared an artificial intelligence tool designed to detect undiagnosed valvular heart disease through analysis of standard 12-lead electrocardiograms. The AI algorithm enables screening for structural heart conditions using routine ECG data without requiring echocardiography.
Digest: This screening tool could facilitate earlier identification of valve disease patients who may be candidates for structural heart interventions, potentially expanding the treatable patient population.